United Therapeutics anticipates potential 2027 approvals for ralinepag and Tyvaso IPF while holding 2026 revenue outlook unchanged (NASDAQ:UTHR)
· seekingalpha.com
United Therapeutics (UTHR) Q2 2026 earnings call: Tyvaso trends, $783M revenue, FDA filings for IPF/PAH and 2027 catalysts.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...